RecruitingNot ApplicableNCT06366425

Screening for Chronic Liver Diseases in General Population

Non-invasive Screening for Chronic Liver Diseases in the General Population. A Prospective Study


Sponsor

University Hospital, Montpellier

Enrollment

260 participants

Start Date

Sep 11, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.


Eligibility

Min Age: 40 Years

Inclusion Criteria3

  • Age ≥ 40 years
  • Without known liver pathologies
  • Having at least one risk factor for chronic liver disease: risky consumption of alcoholic beverages according to the AUDIT questionnaire, the presence of metabolic syndrome, diabetes or a risk factor for viral hepatitis B, D or C.

Exclusion Criteria7

  • Fibroscan already performed in the last 12 months
  • Failure to collect express oral consent
  • Patient not affiliated with or not benefiting from a national health insurance scheme
  • Patient protected by law
  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Pregnant or breastfeeding woman

Interventions

DIAGNOSTIC_TESTBlood sample then fibroscan

The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test. If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan.


Locations(1)

CHU de Montpellier

Montpellier, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06366425


Related Trials